MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

4.890 -0.770 (-13.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,555,493
Open 5.450
Bid (Size) 4.890 (100)
Ask (Size) 4.980 (5,000)
Prev. Close 5.660
Today's Range 4.750 - 5.538
52wk Range 4.010 - 11.24
Shares Outstanding 77,740,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verastem Q1 Earnings Call Highlights ↗
Verastem (NASDAQ:VSTM) reported first-quarter 2026 net product revenue of $18.7 million for AVMAPKI FAKZYNJA CO-PACK, as management said the launch of the therapy for KRAS-mutated recurrent low-grade... 
Via MarketBeat
Topics Earnings
News headline image
Verastem (VSTM) Q1 2026 Earnings Transcript ↗
Verastem (VSTM) Q1 2026 Earnings Transcript 
Via The Motley Fool

Performance

YTD
-32.4%
-32.4%
1 Month
-7.9%
-7.9%
3 Month
-26.5%
-26.5%
6 Month
-40.7%
-40.7%
1 Year
-32.9%
-32.9%

More News

Read More
News headline image
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss ↗
Via Chartmill
Verastem Inc. (NASDAQ:VSTM) Reports Strong Q4 Revenue Beat, Narrows Loss Amid Product Launch ↗
Via Chartmill
News headline image
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
From Verastem Oncology
Via Business Wire
News headline image
Verastem (VSTM) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? ↗
Via Stocktwits
Topics Earnings
News headline image
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
News headline image
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
Via The Motley Fool
News headline image
Verastem Oncology Stock Drops After Hours After Discontinuing A Clinical Trial In Lung Cancer ↗
Via Stocktwits
Topics Supply Chain
News headline image
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
From Verastem Oncology
Via Business Wire
News headline image
This Biotech Is Up 194% in a Year but One Investor Took Millions Off the Table ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
From Verastem Oncology
Via Business Wire
News headline image
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 4.890
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 05/08/26 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 380.15M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 380M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story